2 results
Approved WMOWill not start
Part 1 - To determine effects of different ianalumab doses on ALT normalization at Week 24 in patients with AIH who are incomplete responders or intolerant to standard therapy.Part 2 - To confirm the efficacy (biochemical and histological remission…
Approved WMORecruiting
To determine the dose-response relationship of VAY736 for key efficacy and safety parameters.